Meta-analyses of randomized controlled trials looks at efficacy of semaglutide (Ozempic) in treating people suffering with obesity

Dr. Barry Dworkin

Medical Mythbusting Commentary for December 19, 2022

Meta-analyses of randomized controlled trials looks at efficacy of semaglutide (Ozempic) in treating people suffering with obesity Play Now | Play in Popup | Download

Source:
Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs)

Related posts:

  1. Treatments for weight loss do exist, work well for many, and reveal our growing understanding of how our homeostatic, motivational, and executive brain centers interact with respect to weight control.
  2. Wegovy (semaglutide) approved by FDA to support people struggling to lose weight (and that includes many). Health Canada did so in November 2021. Major addition to weight-loss management options.
  3. Diabetes drug in short supply in U.S. (but not in Canada) after celebrities, influencers touted its weight-loss benefits.
  4. NEJM publishes study evaluating the use of semaglutide to assist people with weight loss. Not “game-changing” but another positive step forward for evidenced-based treatment to help people with #Overweight or #Obesity.
Bitnami